about
Microenvironment drug resistance in multiple myeloma: emerging new players.Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia.Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis: A case reportBone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomesSuspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial MassCAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic CancerDifference in growth hormone response to growth hormone-releasing hormone (GHRH) testing following GHRH subacute treatment in normal aging and growth hormone-deficient adults: possible perspectives for therapeutic use of GHRH or its analogs in elderRhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myelomaCIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System InvolvementBortezomib Treatment Modulates Autophagy in Multiple MyelomamiR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In VitroBone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patientsRAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RASBone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature reviewEmerging role of Immune Checkpoint Inhibitors in Hepatocellular CarcinomaPredictive and Prognostic Factors in HCC Patients Treated with SorafenibInsights into the Regulation of Tumor Angiogenesis by Micro-RNAsGene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot StudyHigh-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentExploration of Artificial Intelligence Use with ARIES in Multiple Myeloma ResearchLong-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature reviewMechanisms of Resistance to Anti-CD38 Daratumumab in Multiple MyelomaHB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple MyelomaSkeletal Metastases of Unknown Primary: Biological Landscape and Clinical OverviewMicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug ResistanceHalting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progressionImmune Checkpoint Inhibitor-Related Myositis: From Biology to BedsideAnti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
P50
Q38913083-64846DEB-7E2A-452B-A8AB-7759E862262DQ39134426-A390E53B-A710-4D85-B9C2-98230556B47EQ47610951-3C92CA9B-BDDB-4968-9120-3E90C06F8B69Q47699487-992609EB-EA8E-4BA6-BBA8-83843A4A2E14Q49388828-B5AC1D94-2255-46A7-AD7A-88F2AC7FF2A0Q51732175-8AFD618A-C553-4467-A3EF-62E337653505Q54110134-4B80F6A4-5C3A-4BBA-A759-44D827B208CEQ54323070-1F0CC93C-7A2E-4AB2-9D67-29069ACF50B4Q57128050-E9B34A3C-3E98-4C1C-95B9-5767D72B7B38Q57787647-D8E635E1-E0DF-498D-818D-760EDD3631AFQ58695482-AC38059F-BCE3-4554-8A8E-EAB542589ABDQ64119749-895DB7AB-DB9D-4A01-8779-1BBF6F81AC2AQ85033886-D87CDD88-BEDF-4EB7-840D-F626CA8D1911Q88197211-A79CC4FB-DDC2-4D6B-A27C-0DE987D2EE07Q89647087-D019FC4F-3E9E-4638-8960-4A5FE1FA6A92Q89834625-EC3B8D03-FF7F-4722-9A80-2B8B2EEB0215Q90047902-4C80967D-D48A-4C82-8F5C-DF836D5950D1Q90468255-C3FF73A2-D86E-4E4B-9E94-2FD1124DF0A1Q90638601-CE305DA7-BEE7-4473-96C6-DCBF44376CB1Q90783761-6B0DCD8C-308C-402E-B9AF-9B308CF13356Q90803543-ECEDDD67-AA03-4CAD-BD58-55B076AEEC0FQ90877592-62B05B67-252E-41F6-BD22-A06BD09E5D84Q91400408-9F6E32A7-3CAE-423D-AEF8-AF05093AEA37Q91658635-AE8B6967-5576-4CED-A23B-F19E916185B9Q92027921-61865B4D-3BA0-4B0B-9346-B7B8F6479B2AQ92028426-98929CA5-B044-4ECF-8EB2-6E579C813E35Q92359134-1A75F161-610B-45E8-A83F-747FD775E75CQ92636053-2F81AD44-B7E0-472E-9432-5D8246F7290AQ92636657-38E15FB8-F2D5-4925-A0FB-D96C3BFE8CF0Q93016715-7D386300-349A-4884-8C1A-AEACCAA67A99Q94459517-C16748F7-623E-4022-8AE3-ECE4EB25CEFCQ94473319-E1D15714-DAF2-48B1-88B7-C5F199224EB2Q94480526-30F67E58-C91B-4941-9E79-FAA00F396452Q95833061-816B3581-7C6F-4ADE-91D3-717A7851205C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio Giovanni Solimando
@ast
Antonio Giovanni Solimando
@en
Antonio Giovanni Solimando
@es
Antonio Giovanni Solimando
@nl
type
label
Antonio Giovanni Solimando
@ast
Antonio Giovanni Solimando
@en
Antonio Giovanni Solimando
@es
Antonio Giovanni Solimando
@nl
prefLabel
Antonio Giovanni Solimando
@ast
Antonio Giovanni Solimando
@en
Antonio Giovanni Solimando
@es
Antonio Giovanni Solimando
@nl
P106
P1153
55253101400
P21
P31
P496
0000-0002-2293-9698